Sparingvision
A clinical-stage genomic medicines company that develops mutation-independent gene therapies for inherited retinal diseases.
Sparingvision has raised €135M across 3 funding rounds from 7 investors, most recently a Series B round in Sep 2022. Based in Paris, France; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€135M
€135,000,000
Funding rounds
3
Investors
7
distinct backers
Active since
2017-07
latest 2022-09
Funding by year
EUR raised per yearSparingvision — funding by year — interactive chart.
Data table
| Sparingvision — funding by year | |
|---|---|
| 2017 | €16M |
| 2020 | €45M |
| 2022 | €75M |
Signals
High confidenceRaise-next likelihood10
base rate 48% for Series B
- ▼ Past typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-14 | Series B | €75M | 4BIO Capital,Bpifrance,Jeito Capital,RD Fund,UPMC Enterprises,Ysios Capital | View deal → |
| 2020-10-21 | Other | €45M | 4BIO Capital,UPMC Enterprises | View deal → |
| 2017-07-07 | Other | €16M | Bpifrance,Fondation Fighting Blindness Clinical Research Institute | View deal → |
Investors
7Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData